Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review

• Published in: Translational andrology and urology 2020-06, Vol.9 (3), p.1415-1427
• Main Authors: Lebastchi, Amir H., Gupta, Nikhil, DiBianco, John M., Piert, Morand, Davenport, Matthew S., Ahdoot, Michael A., Gurram, Sandeep, Bloom, Jonathan B., Gomella, Patrick T., Mehralivand, Sherif, Turkbey, Baris, Pinto, Peter A., George, Arvin K.
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2223-4683; 2223-4691; 2223-4691
• DOI: 10.21037/tau.2020.03.20

Conventional staging for prostate cancer (PCa) is performed for men diagnosed with unfavorable-intermediate or higher risk disease. Computed tomography (CT) of the abdomen and pelvis and whole body bone scan remains the standard of care for the detection of visceral, nodal, and bone metastasis. The implementation of the 2012 United States Preventive Services Task Force recommendation against routine prostate specific antigen (PSA) screening resulted in a rise of metastatic PCa at the time of diagnosis, emphasizing the importance of effective imaging modalities for evaluating metastatic disease. CT plays a major role in clinical staging at the time of PCa diagnosis, but multi-parametric magnetic resonance imaging (MRI) is now integrated into many prostate biopsy protocols for the detection of primary PCa, and may be a surrogate for CT for nodal staging. Current guidelines incorporate both CT and MRI as appropriate cross-sectional imaging modalities for the identification of nodal metastasis in indicated patients. There is an ongoing debate about the utility of traditional cross-sectional imaging modalities as well as advanced imaging modalities in detection of both organ-confined PCa detection and nodal involvement.